Literature DB >> 35102709

Toward better assessments of developmental toxicity using stem cell-based in vitro embryogenesis models.

Yusuke Marikawa1.   

Abstract

In the past few decades, pluripotent stem cells have been explored as nonanimal alternatives to assess the developmental toxicity of chemicals. To date, numerous versions of stem cell-based assays have been reported that are allegedly effective. Nonetheless, none of the assays has become the gold standard in developmental toxicity assessment. Why? This article discusses several issues in the hope of facilitating the refinement of stem cell assays and their acceptance as the cornerstone in predictive developmental toxicology. Each stem cell assay is built on a limited representation of embryogenesis, so that multiple assays are needed to detect the diverse effects of various chemicals. To validate and compare the strengths and weaknesses of individual assays, standardized lists of reference chemicals should be established. Reference lists should consist of exposures defined by toxicokinetic data, namely maternal plasma concentrations that cause embryonic death or malformations, and also by the effects on the molecular machineries that control embryogenesis. Although not entirely replacing human or animal tests, carefully selected stem cell assays should serve as practical and ethical alternatives to proactively identify chemical exposures that disturb embryogenesis. To achieve this goal, unprecedented levels of coordination and conviction are required among research and regulatory communities.
© 2022 The Author. Birth Defects Research published by Wiley Periodicals LLC.

Entities:  

Keywords:  Daston list; adverse outcome pathway; embryo; embryotoxicity; gastruloid; risk assessment; teratogen

Mesh:

Year:  2022        PMID: 35102709      PMCID: PMC9339025          DOI: 10.1002/bdr2.1984

Source DB:  PubMed          Journal:  Birth Defects Res            Impact factor:   2.661


  55 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop.

Authors:  Philip Marx-Stoelting; Els Adriaens; Hans-Jürgen Ahr; Susanne Bremer; Bernward Garthoff; Heinz-Peter Gelbke; Aldert Piersma; Cristian Pellizzer; Ulrike Reuter; Vera Rogiers; Barbara Schenk; Silke Schwengberg; Andrea Seiler; Horst Spielmann; Margino Steemans; Donald B Stedman; Philippe Vanparys; Joan Albert Vericat; Miriam Verwei; Femke van der Water; Marc Weimer; Michael Schwarz
Journal:  Altern Lab Anim       Date:  2009-07       Impact factor: 1.303

3.  Morphology-based mammalian stem cell tests reveal potential developmental toxicity of donepezil.

Authors:  Caroline G Y Lau; Yusuke Marikawa
Journal:  Mol Reprod Dev       Date:  2014-09-30       Impact factor: 2.609

4.  A selection of candidate compounds for in vitro teratogenesis test validation.

Authors:  M K Smith; G L Kimmel; D M Kochhar; T H Shepard; S P Spielberg; J G Wilson
Journal:  Teratog Carcinog Mutagen       Date:  1983

Review 5.  Endoderm and mesoderm derivatives in embryonic stem cell differentiation and their use in developmental toxicity testing.

Authors:  R H Mennen; M M Oldenburger; A H Piersma
Journal:  Reprod Toxicol       Date:  2021-11-30       Impact factor: 3.143

Review 6.  Maternal factors in developmental toxicity.

Authors:  J M DeSesso
Journal:  Teratog Carcinog Mutagen       Date:  1987

Review 7.  Hypoglycaemia in pregnancy.

Authors:  B Persson; U Hansson
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-07

8.  Co-culture of rat embryos and hepatocytes: in vitro detection of a proteratogen.

Authors:  L A Oglesby; M T Ebron; P E Beyer; B D Carver; R J Kavlock
Journal:  Teratog Carcinog Mutagen       Date:  1986

Review 9.  The nature of embryonic stem cells.

Authors:  Graziano Martello; Austin Smith
Journal:  Annu Rev Cell Dev Biol       Date:  2014       Impact factor: 13.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.